Merck Is Now Pursuing Two Coronavirus Vaccines — Is Merck Stock A Buy?Investors Business Daily • 08/27/20
Merck Analyst Raises Price Target Ahead Of Upcoming Antiviral Trial Results, PresentationBenzinga • 08/25/20
Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal CancerBusiness Wire • 08/19/20
T Cell Responses To Coronavirus Vaccines Are In The Interest Of National SecuritySeeking Alpha • 08/10/20
Merck KGaA (MKGAF) CEO Stefan Oschmann on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/08/20
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatmentMarket Watch • 08/07/20
Pfizer, Merck, and Others See a Slowdown in Vaccine Sales, but Anticipate an Autumn ReboundThe Motley Fool • 08/06/20
5 Large Biotechs and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-1924/7 Wall Street • 08/05/20
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)Business Wire • 08/04/20